Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BMS Forms Translation Partnership with Tsinghua University

publication date: Jul 24, 2018

Bristol-Myers Squibb formed a new collaboration with Beijing's Tsinghua University to develop drugs for novel targets associated with autoimmune disease and cancer. The University's Innovation Center for Immune Therapy will do the research on the projects while BMS will have an option to license the candidates. In 2012, BMS collaborated with Tsinghua to discover targets and map their 3-D structural biology (see story). Now, the two entities are moving into drug development. BMS says the new collaboration shows its continued support of novel drug development in China. More details....

Stock Symbol: (NYSE: BMY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.